Expansion of the Health and Diagnostics Business Using Amino Acid Technology
First written in FY2016. 7 of 11 entries say "Advanced", first in FY2017. Latest entry: FY2023.
3 other companies' latest entry also says "Advanced".
- FY2023AdvancedAnnual report
「In September 2022, the website for healthcare professionals was substantially redesigned. In addition, a new paper related to AminoIndex technology, concerning blood essential amino acid concentrations and the future onset of Alzheimer's-type dementia, was published in Frontiers in Nutrition.」
AminoIndex technology was expanded into an information platform for healthcare professionals and research on the risk of dementia onset, advancing its implementation in diagnostics and health management. - FY2022AdvancedAnnual report
「In April 2021, the lifestyle-improvement support app aminoステップ® was launched, providing functions and solutions useful for daily health management, including registration of AIRS® results, walking rallies, and simple meal logs.」
AIRS® was expanded from a standalone test into a lifestyle-improvement support app, with the Group advancing its development as a health management service through data analysis with Hirosaki University and adoption in insurance products. - FY2021AdvancedAnnual report
「In October, AIRS® added a risk assessment service for preventing cognitive decline. Going forward, in addition to AIRS®, the Group will develop AIRS® services as a platform for proposing lifestyle-improvement solutions, including developing and launching a smartphone app.」
AIRS® was expanded from the three major diseases to prevention of cognitive decline, and progressed to analysis of health big data with Hirosaki University and lifestyle-improvement proposals through a smartphone app. - FY2020AdvancedAnnual report
「In August 2019, the Group entered into a joint research agreement with Shijonawate City, Osaka Prefecture, on analysis of resident health screenings and began initiatives to raise health awareness among residents and encourage them to review their lifestyles. In October, it agreed to a business partnership with Taiyo Life Insurance Co., Ltd. and others on prevention of the three major diseases, and is also considering joint research that could further promote AIRS® and lead to the development of new services.」
AIRS® was expanded into analysis of resident health screenings with local governments, partnerships with insurers on prevention of the three major diseases, and research on patient-stratification markers. - FY2019AdvancedAnnual report
「In April 2019, AIRS® added assessment of the risk of developing a stroke or myocardial infarction within 10 years, enabling assessment of the three major diseases from a single blood sample.」
AIRS added assessment of the risk of developing a stroke or myocardial infarction within 10 years, expanding the service to cover the three major diseases. - FY2018AdvancedAnnual report
「In November 2017, AminoIndex® Risk Screening (AIRS®) was launched nationwide, adding AminoIndex® Lifestyle Disease Risk Screening (AILS (エーアイエルエス)®), which assesses the future risk of developing lifestyle-related diseases, to AICS®. The Group will use this technology to continue developing tests that contribute to disease prevention and early detection, and will develop AIRS® into a comprehensive health indicator.」
AIRS, which added lifestyle-related disease risk assessment to the conventional cancer risk assessment, was launched nationwide, expanding the scope of the diagnostics business. - FY2017AdvancedAnnual report
「AminoIndex® Cancer Risk Screening (AICS®), which uses this technology, is a test that can assess the likelihood of developing multiple cancers from a single blood sample. It is already available at approximately 1,200 medical institutions nationwide.」
The number of medical institutions nationwide offering AICS increased to approximately 1,200. In addition, sales of the regenerative medicine culture medium StemFit® Basic02 began in the US in September 2016 and in South Korea in March 2017. - FY2017-Q3RestatedAnnual report
「The Group will use its proprietary advanced biotechnology to develop high-functionality biomaterials, promote fermentation using fewer resources, and expand into businesses such as culture media for regenerative medicine and diagnostics using AminoIndex technology, thereby driving growth.」
The diagnostics business using AminoIndex technology has continued as one of the growth areas leveraging advanced biotechnology. - FY2017-Q2RestatedAnnual report
「The Group will use its proprietary advanced biotechnology to develop high-functionality biomaterials, promote fermentation using fewer resources, and expand into businesses such as culture media for regenerative medicine and diagnostics using AminoIndex technology, thereby driving growth.」
The diagnostics business using AminoIndex technology has continued as one of the growth areas leveraging advanced biotechnology. Research and development expenses were ¥14,656 million. - FY2017-Q1RestatedAnnual report
「The Group will use its proprietary advanced biotechnology to develop high-functionality biomaterials, promote fermentation using fewer resources, and expand into businesses such as culture media for regenerative medicine and diagnostics using AminoIndex technology, thereby driving growth.」
The diagnostics business using AminoIndex technology has continued as one of the growth areas leveraging advanced biotechnology. - FY2016First statedAnnual report
「AminoIndex technology is a proprietary technology that identifies an individual's current health status and disease risks, including cancer, based on the balance of amino acid concentrations in the blood.」
AICS became available at more than 1,100 medical institutions nationwide, and pancreatic cancer was added in August 2015. The company also expanded into foods with function claims and culture media for regenerative medicine.